ALXO Alx Oncology Holdings Inc

Price (delayed)

$15.5

Market cap

$777.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.74

Enterprise value

$764.59M

ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ...

Highlights

Alx Oncology Holdings's equity has decreased by 28% YoY but it has increased by 12% QoQ

The quick ratio has declined by 46% year-on-year and by 6% since the previous quarter

ALXO's net income is down by 30% year-on-year and by 10% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://alxoncology.com

Peers: OMER OMGA

Key stats

What are the main financial stats of ALXO

Market

Shares outstanding

50.15M

Market cap

$777.36M

Enterprise value

$764.59M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

4.07

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$159.24M

EBITDA

-$158.4M

Free cash flow

-$131.64M

Per share

EPS

-$3.74

Free cash flow per share

-$3.06

Book value per share

$3.81

Revenue per share

TBVPS

$5.64

Balance sheet

Total assets

$242.55M

Total liabilities

$52.84M

Debt

$9.64M

Equity

$189.71M

Working capital

$152.66M

Liquidity

Debt to equity

0.05

Current ratio

5.24

Quick ratio

5.08

Net debt/EBITDA

0.08

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-65.2%

Return on equity

-79.3%

Return on invested capital

-82.6%

Return on capital employed

-77.1%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ALXO stock price

How has the Alx Oncology Holdings stock price performed over time

Intraday

8.92%

1 week

6.97%

1 month

32.03%

1 year

158.33%

YTD

4.1%

QTD

39.01%

Financial performance

How have Alx Oncology Holdings's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$170.28M

Net income

-$160.81M

Gross margin

N/A

Net margin

N/A

ALXO's operating income is down by 34% YoY and by 10% QoQ

ALXO's net income is down by 30% year-on-year and by 10% since the previous quarter

Growth

What is Alx Oncology Holdings's growth rate over time

Valuation

What is Alx Oncology Holdings stock price valuation

P/E

N/A

P/B

4.07

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

The EPS is down by 23% year-on-year and by 4.8% since the previous quarter

The price to book (P/B) is 108% more than the last 4 quarters average of 1.8

Alx Oncology Holdings's equity has decreased by 28% YoY but it has increased by 12% QoQ

Efficiency

How efficient is Alx Oncology Holdings business performance

ALXO's return on equity has dropped by 94% year-on-year and by 20% since the previous quarter

The return on assets has dropped by 76% year-on-year and by 17% since the previous quarter

ALXO's return on invested capital has dropped by 56% year-on-year and by 17% since the previous quarter

Dividends

What is ALXO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALXO.

Financial health

How did Alx Oncology Holdings financials performed over time

The quick ratio has declined by 46% year-on-year and by 6% since the previous quarter

Alx Oncology Holdings's current ratio has decreased by 45% YoY and by 7% from the previous quarter

The debt is 95% smaller than the equity

Alx Oncology Holdings's equity has decreased by 28% YoY but it has increased by 12% QoQ

Alx Oncology Holdings's debt to equity has increased by 25% YoY but it has decreased by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.